Michael C Peters

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8069056/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts. Lancet Respiratory Medicine,the, 2016, 4, 574-584.	10.7	375
2	COVID-19–related Genes in Sputum Cells in Asthma. Relationship to Demographic Features and Corticosteroids. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 83-90.	5.6	370
3	Inflammatory and Comorbid Features of Patients with Severe Asthma and Frequent Exacerbations. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 302-313.	5.6	346
4	Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. Journal of Clinical Investigation, 2018, 128, 997-1009.	8.2	337
5	Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. Journal of Allergy and Clinical Immunology, 2014, 133, 388-394.e5.	2.9	282
6	Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes. Diabetes Care, 2020, 43, 5-12.	8.6	220
7	Baseline Features of the Severe Asthma Research Program (SARP III) Cohort: Differences with Age. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 545-554.e4.	3.8	210
8	Extracellular DNA, Neutrophil Extracellular Traps, and Inflammasome Activation in Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1076-1085.	5.6	165
9	Alternative splicing of interleukin-33 and type 2 inflammation in asthma. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 8765-8770.	7.1	139
10	Refractory airway type 2 inflammation in a large subgroup of asthmatic patients treated with inhaled corticosteroids. Journal of Allergy and Clinical Immunology, 2019, 143, 104-113.e14.	2.9	135
11	Evidence for Exacerbation-Prone Asthma and Predictive Biomarkers of Exacerbation Frequency. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 973-982.	5.6	105
12	Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma. Lancet, The, 2020, 395, 371-383.	13.7	102
13	A Transcriptomic Method to Determine Airway Immune Dysfunction in T2-High and T2-Low Asthma. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 465-477.	5.6	98
14	Obesity alters pathology and treatment response in inflammatory disease. Nature, 2022, 604, 337-342.	27.8	93
15	Multiview Cluster Analysis Identifies Variable Corticosteroid Response Phenotypes in Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1358-1367.	5.6	91
16	New-onset asthma among soldiers serving in Iraq and Afghanistan. Allergy and Asthma Proceedings, 2010, 31, 67-71.	2.2	86
17	Natural killer cell–mediated inflammation resolution is disabled in severe asthma. Science Immunology, 2017, 2, .	11.9	76
18	Use of Fractional Exhaled Nitric Oxide to Guide the Treatment of Asthma: An Official American Thoracic Society Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2021, 204, e97-e109.	5.6	69

MICHAEL C PETERS

#	Article	IF	CITATIONS
19	Airway epithelium–shifted mast cell infiltration regulates asthmatic inflammation via IL-33 signaling. Journal of Clinical Investigation, 2019, 129, 4979-4991.	8.2	57
20	Diagnosis and Management of T2-High Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 442-450.	3.8	51
21	IL1RL1 asthma risk variants regulate airway type 2 inflammation. JCI Insight, 2016, 1, e87871.	5.0	42
22	Mucus Plugs Persist in Asthma, and Changes in Mucus Plugs Associate with Changes in Airflow over Time. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1036-1045.	5.6	39
23	Investigation of the relationship between IL-6 and type 2 biomarkers in patients with severe asthma. Journal of Allergy and Clinical Immunology, 2020, 145, 430-433.	2.9	38
24	Intelectin-1 Is a Prominent Protein Constituent of Pathologic Mucus Associated with Eosinophilic Airway Inflammation in Asthma. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1005-1007.	5.6	35
25	Unmet Needs in Severe Asthma Subtyping and Precision Medicine Trials. Bridging Clinical and Patient Perspectives. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 823-829.	5.6	31
26	ALX receptor ligands define a biochemical endotype for severe asthma. JCI Insight, 2017, 2, .	5.0	29
27	PrecISE: Precision Medicine in Severe Asthma: An adaptive platform trial with biomarker ascertainment. Journal of Allergy and Clinical Immunology, 2021, 147, 1594-1601.	2.9	27
28	Metabolic consequences of obesity as an "outside in―mechanism of disease severity in asthma. European Respiratory Journal, 2016, 48, 291-293.	6.7	25
29	An antiâ€siglecâ€8 antibody depletes sputum eosinophils from asthmatic subjects and inhibits lung mast cells. Clinical and Experimental Allergy, 2020, 50, 904-914.	2.9	24
30	The Precision Interventions for Severe and/or Exacerbation-Prone (PrecISE) Asthma Network: An overview of Network organization, procedures, and interventions. Journal of Allergy and Clinical Immunology, 2022, 149, 488-516.e9.	2.9	24
31	Location of eosinophils in the airway wall is critical for specific features of airway hyperresponsiveness and T2 inflammation in asthma. European Respiratory Journal, 2022, 60, 2101865.	6.7	18
32	Type 2 Immune Responses in Obese Individuals with Asthma. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 633-634.	5.6	15
33	Responsiveness to Parenteral Corticosteroids and Lung Function Trajectory in Adults with Moderate-to-Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 841-852.	5.6	14
34	Biomarkers of Airway Type-2 Inflammation and Integrating Complex Phenotypes to Endotypes in Asthma. Current Allergy and Asthma Reports, 2016, 16, 71.	5.3	12
35	The precision interventions for severe and/or exacerbation-prone asthma (PrecISE) adaptive platform trial: statistical considerations. Journal of Biopharmaceutical Statistics, 2020, 30, 1026-1037.	0.8	11
36	The association of plasma IL-6 with measures of asthma morbidity in a moderate-severe pediatric cohort aged 6-18 years. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2916-2919.e2.	3.8	11

MICHAEL C PETERS

#	ARTICLE	IF	CITATIONS
37	Update in Adult Asthma 2020. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 395-402.	5.6	8
38	Hyperresponsiveness on Washout of Volatile Anesthetics from Isolated Spinal Cord Compared to Withdrawal from Ethanol. Anesthesia and Analgesia, 2005, 100, 413-436.	2.2	6
39	Internet-Based Monitoring in the Severe Asthma Research Program Identifies a Subgroup of Patients With Labile Asthma Control. Chest, 2018, 153, 378-386.	0.8	6
40	Reply to Nannini and to Lipworth et al American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1325-1326.	5.6	0
41	Novel Potential Treatable Traits in Asthma: Where is the research taking us?. , 2022, , .		0